#EHA2024: Late-phase trials in AML

To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up here with our live social media relating to late-phase trials in acute myeloid leukemia (AML).

CONGRESS | #EHA2024
In the plenary abstracts session, Uwe Platzbecker @UwePlatzbecker @UniLeipzig presents the first results from the open-label randomized phase III APOLLO trial of ATO with ATRA and Ida vs standard ATRA plus chemotherapy regimen in 131 patients with ND HR #APL.… pic.twitter.com/uwp7y5ngi3

— AML Hub (@AML_Hub) June 15, 2024

CONGRESS | #EHA2024
Maria Teresa Voso @unitorvergata presents a post-hoc analysis of patients with AML-MRC who received oral azacitidine (n=56) vs placebo (n=45) maintenance in the QUAZAR AML-001 trial.
▪️ Oral Aza improved OS (19.9 months vs 14.8 months), RFS (7.5 months vs 3.7… pic.twitter.com/ixHcjYBnZQ

— AML Hub (@AML_Hub) June 15, 2024

CONGRESS | #EHA2024
Mikkael A. Sekeres @MikkaelSekeres @SylvesterCancer @UMiamiHealth discusses an exploratory analysis of continuation therapy impact on quizartinib efficacy in patients with ND FLT3m AML in the phase III QuANTUM-First trial.
▪️ In patients who received… pic.twitter.com/xJ1Li2Y0Yr

— AML Hub (@AML_Hub) June 15, 2024

CONGRESS #EHA2024 | Andrius Žučenka @zucenka @VU_LT reports efficacy and safety of the quadruplet G-ACTIVE (gilteritinib+actinomycin D+cytarabine+venetoclax) salvage treatment in pts with FLT3m R/R AML (N=25). Among 16 pts meeting the inclusion criteria of the phase III ADMIRAL… pic.twitter.com/MwJgfyue48

— AML Hub (@AML_Hub) June 16, 2024

CONGRESS | #EHA2024 | Poster
James Foran @MayoClinic presents long-term data from the phase III SIERRA trial of 131I-apamstamab (Iomab-B, an anti-CD45 radioimmuoconjugate)-led HSCT vs conventional care in older patients with R/R AML.
▪️ Primary endpoint was met: dCR = 22% vs 0%… pic.twitter.com/zDSQ4VYkFb

— AML Hub (@AML_Hub) June 18, 2024

CONGRESS #EHA2024 | Naval Daver @Daver_Leukemia @MDAndersonNews presents findings of the phase III ENHANCE-3 study (NCT05079230) evaluating efficacy and safety of magrolimab (vs placebo) in combination with azacitidine and venetoclax in pts with previously untreated AML… pic.twitter.com/4xDfR7XLjG

— AML Hub (@AML_Hub) June 15, 2024

CONGRESS #EHA2024 | Andrew Wei @PeterMacCC shares outcomes from the QUAZAR AML-001 trial, evaluating the impact of TP53 mutations on clinical response in 310 pts with AML during oral azacitidine maintenance therapy.
▪️ Among 15% pts with TP53mut at BL, mRFS was 7.4 vs 3.5 months… pic.twitter.com/FHKtG5npVv

— AML Hub (@AML_Hub) June 15, 2024